◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY

HomeAll stocks0-9 › 6681

BrainAurora Medical Technology Limited (6681) Financial History

4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.

Healthcare · Health Information Services · DATA UPDATED 2026-08-10

BrainAurora Medical Technology Limited (6681) operates in the Health Information Services industry and is headquartered in Shaoxing, China with about 165 employees. Its market capitalization is roughly CNY 2 billion. In the fiscal year ended 2025-12-31, 6681 reported CNY 220M in revenue and (CNY 315M) in net income.

BrainAurora Medical Technology Limited provides system integral software solutions for hospitals and research projects in Mainland China. The company develops medical-grade digital therapy (DTx) products for cognitive impairment.

Interactive charts & full statements →

6681 Revenue & Earnings History — Annual Income Statement

Income statement2025-12-312024-12-312023-12-312022-12-312021-12-31
Total RevenueCNY 220MCNY 122MCNY 67MCNY 11M
Gross ProfitCNY 90MCNY 54MCNY 32MCNY 3M
Operating Income (EBIT)(CNY 250M)(CNY 172M)(CNY 152M)(CNY 104M)
Net Income(CNY 315M)(CNY 198M)(CNY 359M)(CNY 502M)

CNY; CNYM / CNYB as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

6681 Free Cash Flow History

6681 Balance Sheet History

Balance sheet2025-12-312024-12-312023-12-312022-12-312021-12-31
Total AssetsCNY 733MCNY 600MCNY 395MCNY 418M
Total LiabilitiesCNY 637MCNY 1.1BCNY 727MCNY 1.5B

CNY; CNYM / CNYB as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive 6681 viewer.

Other Companies in Health Information Services

← 6680All “0-9” companies6682 →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.